NTLA

Intellia Therapeutics, Inc. NGM · NTLA

$11.13 -0.34 (-2.96%)

Deep pullback · -2.41σ Hot zone

+ Compare Open in Sniper

Valuation

Market cap $1.6B

P/E (ttm) —

Forward P/E -6.3

Beta (5y) 1.77

Shares out 139.7M

Div yield —

Profitability & returns

ROE -56.3%

Net margin —

FCF margin -355.9%

Debt / equity 0.13

Trading information

Last price $11.13

Day range $11.07 – $11.46

52-wk range $10.91 – $18.48

Avg volume 7.0M

RSI (2) 31.3

Trend zone Deep pullback

52-week range · today's price

$10.91$18.48

Company

Sector Healthcare

Industry Biotechnology

Exchange NGM

Next earnings 2026-08-06

Intellia Therapeutics, Inc. operates as a clinical-stage genome editing company focused on developing potentially curative therapeutics using CRISPR/Cas9-based technologies. The company offers clustered, regularly interspaced short palindromic repeats (CRISPR)/CRISPR associated 9 (Cas9) technology for genome editing. The company provides a modular platform, to advance in vivo and ex vivo therapies for diseases. T…